LLY

1,010.53

-2.15%↓

JNJ

202.19

-1.57%↓

ABBV

228.68

-0.7%↓

UNH

333.72

-1.99%↓

AZN

89.97

-0.96%↓

LLY

1,010.53

-2.15%↓

JNJ

202.19

-1.57%↓

ABBV

228.68

-0.7%↓

UNH

333.72

-1.99%↓

AZN

89.97

-0.96%↓

LLY

1,010.53

-2.15%↓

JNJ

202.19

-1.57%↓

ABBV

228.68

-0.7%↓

UNH

333.72

-1.99%↓

AZN

89.97

-0.96%↓

LLY

1,010.53

-2.15%↓

JNJ

202.19

-1.57%↓

ABBV

228.68

-0.7%↓

UNH

333.72

-1.99%↓

AZN

89.97

-0.96%↓

LLY

1,010.53

-2.15%↓

JNJ

202.19

-1.57%↓

ABBV

228.68

-0.7%↓

UNH

333.72

-1.99%↓

AZN

89.97

-0.96%↓

Kodu・Aktsiate loetelu・Pliant Therapeutics Inc

Pliant Therapeutics Inc

Suletud

1.3 -15.03

Osta Müü

Ülevaade

Aktsiahinna muutus

24h

Praegune

Min

1.15

Max

1.6400000000000001

Põhinäitajad
By Trading Economics
Sissetulek	17M -26M
Aktsiakasum	-0.43
Kasumimarginaal	-2,190.837
Töötajad	171
EBITDA	19M -23M

Soovitused
By TipRanks
Soovitused	Neutraalne
12 kuu keskmine prognoos	+94.81% upside

Turustatistika
By TradingEconomics
Turukapital	-8.5M 94M
Eelmine avamishind	16.33
Eelmine sulgemishind	1.3

Tehniline skoor

By Trading Central

Kindlus

Very Strong Bearish Evidence

1.43 / 1.6 Toetus ja vastupanu

Pliant Therapeutics Inc Graafik

Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.

Seotud uudised

4. dets 2025, 20:41 UTC

Tulu

Suurimad hinnamuutused turgudel

America's Car-Mart Rises on Better-Than-Expected 2Q Revenue, $300 Million Term Loan

4. dets 2025, 18:14 UTC

Omandamised, ülevõtmised, äriostud

Big Yellow Says It Will Terminate Takeover Talks With Blackstone

4. dets 2025, 17:43 UTC

Suurimad hinnamuutused turgudel

Omandamised, ülevõtmised, äriostud

Brera Holdings Signs Non-Binding Term Sheet to Acquire RockawayX

4. dets 2025, 17:01 UTC

Tulu

TD Bank Pushes Up Dividend After Underlying Earnings, Revenue Beat Expectations -- Update

4. dets 2025, 23:45 UTC

Market Talk

Nikkei May Decline Amid Caution Over U.S. Labor Market, Japan Earnings -- Market Talk

4. dets 2025, 23:45 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

4. dets 2025, 21:54 UTC

Market Talk

Global Equities Roundup: Market Talk

4. dets 2025, 21:54 UTC

Market Talk

Warehouse's Strategy to Lift Margins Easier Said Then Done -- Market Talk

4. dets 2025, 21:50 UTC

Market Talk

Financial Services Roundup: Market Talk

4. dets 2025, 21:50 UTC

Market Talk

Basic Materials Roundup: Market Talk

4. dets 2025, 21:48 UTC

Market Talk

Scales Hits Mark With Earnings Guidance -- Market Talk

4. dets 2025, 21:37 UTC

Tulu

Aerospace Start-Up Beta Posts Its First Earnings Report. The Stock Rises. -- Barrons.com

4. dets 2025, 21:36 UTC

Tulu

These Stocks Moved the Most Today: Meta Platforms, Salesforce, Snowflake, UiPath, Micron, Dollar General, Kroger, and More -- Barrons.com

4. dets 2025, 20:15 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

4. dets 2025, 20:15 UTC

Market Talk

Think Tank Calls For Bank of Canada Rate Hold Next Week -- Market Talk

4. dets 2025, 20:04 UTC

Market Talk

Natural Gas Futures Extend Gains as U.S. Grows Cold -- Market Talk

4. dets 2025, 19:54 UTC

Market Talk

Oil Futures Bolstered by Lasting Ukraine War, U.S. Macro Outlook -- Market Talk

4. dets 2025, 19:44 UTC

Omandamised, ülevõtmised, äriostud

EQB CEO: PC Financial Deal Adds Scale to Compete With Larger Canadian Banks

4. dets 2025, 19:44 UTC

Omandamised, ülevõtmised, äriostud

EQB CEO: PC Financial Tie-Up Brings Scale to Reach More Customers

4. dets 2025, 19:44 UTC

Omandamised, ülevõtmised, äriostud

Equitable Bank Deal for PC Financial Adds Heft to Compete With Canada's Big Banks -- Interview

4. dets 2025, 19:33 UTC

Market Talk

Gold Inches Higher as Traders Continue to Mull ADP Jobs Report -- Market Talk

4. dets 2025, 19:01 UTC

Omandamised, ülevõtmised, äriostud

Paramount Raises Concerns About Netflix's Bid for Warner Bros. Discovery -- WSJ

4. dets 2025, 19:01 UTC

Omandamised, ülevõtmised, äriostud

Paramount Wrote to Warner Bros. Discovery Again Wednesday -- WSJ

4. dets 2025, 19:01 UTC

Omandamised, ülevõtmised, äriostud

Paramount Wrote Netflix Deal With Warner Bros. Would Likely 'Never Close,' Monday Letter Says -- WSJ

4. dets 2025, 19:01 UTC

Omandamised, ülevõtmised, äriostud

Another Round of Bids for Warner Bros. Discovery Due Thursday, Sources Say -- WSJ

4. dets 2025, 18:58 UTC

Market Talk

U.S.-Venezuela Military Tension Expected to Lift Oil Prices -- Market Talk

4. dets 2025, 17:20 UTC

Market Talk

Basic Materials Roundup: Market Talk

4. dets 2025, 17:15 UTC

Market Talk

Global Commodities Roundup: Market Talk

4. dets 2025, 16:41 UTC

Market Talk

Gold Rises as Traders Await U.S. Inflation Data -- Market Talk

4. dets 2025, 16:33 UTC

Market Talk

Tulu

Salesforce Customers Are Gaining Confidence in Agentforce -- Market Talk

Võrdlus sarnastega

Hinnamuutus

Pliant Therapeutics Inc Prognoos

Hinnasiht

By TipRanks

94.81% tõus

12 kuu keskmine prognoos

Keskmine 3 USD 94.81%

Kõrge 4 USD

Madal 2 USD

Põhineb 4 Wall Streeti analüütiku instrumendi Pliant Therapeutics Inc 12 kuu hinnasihil - viimase 3 kuu andmed.

Hinnangu Konsensus

By TipRanks

Neutraalne

4 ratings

Osta

Hoia

Müü

Põhineb 4 analüütiku instrumendi Pliant Therapeutics Inc aktsia reitingul - viimase 3 kuu andmed.

Tehniline skoor

By Trading Central

1.43 / 1.6Toetus ja vastupanu

Recent bearish events outweigh bullish events.

There is one bearish event.

Finantsandmed

Müügi- ja halduskulud

Tegevuskulud

Maksueelne kasum

Müük

Müügikulu

Brutokasum müügist

Intressikulud võla pealt

EBITDA

Ärikasum

Ettevõttest Pliant Therapeutics Inc

Pliant Therapeutics, Inc., a clinical stage biopharmaceutical company, discovers, develops, and commercializes novel therapies for the treatment of fibrosis and related diseases in the United States. The company's lead candidate is bexotegrast, an oral, small-molecule, dual selective inhibitor of avß6 and avß1 integrins, which is in phase 2b trials for idiopathic pulmonary fibrosis and in phase 2a trial for primary sclerosing cholangitis. It also develops PLN-1474, an oral, small-molecule selective inhibitor of avß1 for the treatment of liver fibrosis associated with nonalcoholic steatohepatitis; PLN-101095, a dual inhibitor of integrins avß8 and avß1 for the treatment of solid tumors; and PLN-101325 for treatment of muscular dystrophies. Pliant Therapeutics, Inc. was incorporated in 2015 and is based in South San Francisco, California.